Clinical Research
AdaptCycle
The ADAPTcycle study is designed to investigate whether patients suffering from intermediate-risk breast breast cancer at intermediate risk benefit from treatment with the drug ribociclib (CDK treatment with the drug ribociclib (CDK 4/6 inhibitor) in combination with endocrine therapy therapy than from standard chemotherapy and may therefore be able to avoid and thus possibly save unnecessary chemotherapy.
AdaptLate
The ADAPTlate study is investigating whether the risk of local recurrence or metastases in patients with hormone-dependent breast cancer can be reduced with the help of extended anti-hormonal therapy.
CAMPA
Evaluation of a nurse-led consultation of patients with metastatic breast and ovarian cancer treated with a PARP inhibitor
Cinderella
The CINDERELLA project intends to test and validate the implementation of an AI-based tool for a safer and evidence-based clinical decision for patients proposed for locoregional treatment, making it easily applied in clinical practice anywhere in the world. A better prediction of aesthetic outcomes of the different breast surgical approaches can improve patient satisfaction and quality of life, reduce anxiety and depression levels, as well as potential revisional surgeries.
Eleanor
ELEANOR – designed as a prospective, longitudinal, non-interventional study (NIS) – will investigate real-world use of neratinib and its treatment management in patients with HR-positive, HER2-overexpressing/amplified breast cancer stage I-III having completed adjuvant trastuzumab-based therapy less than one year ago. Data from this study will contribute to a deeper understanding and characterization of the everyday use of neratinib in a broader patient population in the German and Austrian routine setting.
EuMelaReg
Collecting real-world data from melanoma patients across Europe, we aim to build the largest and quickest melanoma registry in the world. Interested societies or cancer treatment centres can help us by joining EUMelaReg – even without an existing registry.
DSMM XVII
Elotuzumab (E), in combination with carfilzomib, lenalidomide and dexamethasone (EKRd) against KRd before and after autologous stem cell transplantation in newly diagnosed multiple myeloma and with subsequent maintenance therapy with elotuzumab and lenalidomide versus lenalidomide monotherapy. A phase III study of the German Multiple Myeloma Study Group.
Fatigo
The FatiGO study, conducted at the University Clinic Cologne, focuses on the immediate effectiveness of targeted exercise therapy on cancer-related fatigue syndrome. It aims to improve life quality, psychological well-being, and physical activity levels in cancer patients. The study, encompassing various exercise interventions, investigates the best approaches to alleviate fatigue syndrome and develop standard oncological exercise therapy.
Minerva
The MINERVA Trial aims to evaluate safety, efficacy and quality of life (QoL) for the combination of Abemaciclib with an Aromatase Inhibitor or Fulvestrant in pre- and postmenopausal patients with metastatic hormone receptor positive HER2 negative breast cancer in the first line setting.
Side effect monitoring and patient reported outcomes will be captured using the web- and app-based CANKADO digital health application. Via this user-friendly tool the patients can document their therapy side effects (e.g. diarrhea) and outcomes on a day-to-day basis. The capturing of side effects using the digital health application will be done additionally to the regular AE documentation.
MY-ACU
The MY-ACU study, conducted at the Comprehensive Cancer Center Mainfranken, investigates the effectiveness of auricular acupressure based on the NADA protocol in patients with Multiple Myeloma. This study focuses on improving quality of life and alleviating symptoms like fatigue, sleep disorders, and pain. It involves a non-invasive, weekly treatment using special acupressure patches applied to the ear, which the patients can self-administer at home.
OMCAT
The OMCAT Register aims to provide learning databases in cancer comprising both PRO data using PRO-React and “ground truth” (outcome data verified by the physician during patient examinations). Intelligent learning and knowledge engineering procedures will utilize this PRO data to provide high-quality event prediction algorithms. The ground-truth data enables so-called “supervised learning” techniques of artificial intelligence, because predicted events can be verified with a high level of certainty from ground-truth data.
PreCycle
In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast cancer treated with the cyclin dependent kinase 4/6 (CDK4/6) Inhibitor Palbociclib in combination with an aromatase inhibitor or fulvestrant. Furthermore this approach will be combined with biomarker screening to identify predictive markers for and to learn more about adherence, symptoms, response, and resistance.
Polar
CIPN is a common, dose-limiting side effect of taxane-based chemotherapy. Currently there is no established strategy for prevention or treatment. Smaller studies suggest that cooling or compression could have a preventive effect. In this randomized trial we investigated the effectiveness of one-sided hand-cooling or compression for the prevention of CIPN.
Ribanna
A non-interventional study for postmenopausal women with HR+/HER2 locally advanced/metastatic breast cancer to evaluate the effectiveness of the treatment algorithm starting with Kisqali® (ribociclib) in combination with an aromatase inhibitor or with endocrine therapy or with chemotherapy as first-line therapy in routine clinical practice.
StomRay
The StomRay study at the Jules Bordet Institute is a prospective pilot study focusing on the dental side effects of radiotherapy in patients treated for head and neck cancer. This interventional trial, currently open for recruitment, is led by investigator Dirk Van Gestel and aims to provide valuable insights into managing these side effects.
SwallPEG
The SwallPEG study at the Jules Bordet Institute is a phase 3 clinical trial investigating the outcomes of prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients. Led by Tatiana Dragan, this interventional study focuses on patient-reported outcomes in terms of swallowing and quality of life following definitive radiotherapy and systemic therapy. The trial is open for recruitment and aims to enhance patient care in oncology.
VinoMetro
The VinoMetro study, a collaborative effort by Johannes Gutenberg University Mainz and Pierre Fabre Pharma GmbH, explored the innovative use of daily oral Vinorelbine in treating advanced/metastatic hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. This research, led by Prof. Dr. Marcus Schmidt aimed to enhance treatment strategies for breast cancer patients.
Research Projects
AI for incident prediction
Transforming Healthcare with AI: The Future of Incident Prediction
Unlock the future of healthcare with CANKADO’s cutting-edge AI for Incident Prediction. Our pioneering project is reshaping patient care by harnessing the predictive power of artificial intelligence. With our advanced algorithms, we’re not just reacting to health incidents – we’re anticipating them, offering a new realm of proactive healthcare solutions.
AI: Your Partner in Health
Imagine a world where health incidents are foreseen and prevented before they happen. That’s the world we’re building at CANKADO. Our AI-driven models analyze health data with unparalleled precision, offering critical insights and predictions that empower healthcare providers to act swiftly and effectively.
Safety, Ethics, and Innovation Combined
At CANKADO, we prioritize your safety and privacy. Our ethical AI solutions are developed with the highest standards of data security, ensuring your health information is always protected. Join us as we embark on this revolutionary journey, where technology meets healthcare to create a safer, healthier tomorrow.
Symptom Clusters
Revolutionizing Healthcare through Symptom Cluster Research
Dive into the future of personalized healthcare with CANKADO’s groundbreaking Symptom Clusters research project. We’re at the forefront of understanding the complex web of symptoms that patients experience, particularly in chronic and cancer care. Our mission? To transform these insights into tailored treatments that address not just individual symptoms, but their interconnected impact on patient health.
Data-Driven, Patient-Centric Approach
Join us in a journey where data meets empathy. Our research doesn’t just crunch numbers; it listens to patients, understanding the nuances of their experiences. By mapping out symptom clusters, CANKADO is setting new standards in symptom management, enabling care that’s as unique as each patient’s experience.
Empowering Healthcare Providers and Patients Alike
Our commitment goes beyond research. It’s about empowering healthcare providers with knowledge and tools for better care. It’s about giving patients a voice in their treatment journey. With CANKADO, symptom management is no longer a guessing game; it’s a precision-driven strategy for improved health outcomes.
SANCO
Experience a new frontier in patient care with CANKADO’s SANCO project, tailored for ALK+ Non-Small Cell Lung Cancer (NSCLC) patients. Harnessing the capabilities of the CANKADO PRO-React APP, SANCO innovatively enhances patient self-management and symptom control. This patient-focused strategy not only betters life quality but also efficiently manages care, lightening the load for healthcare professionals. Step into a proactive and empowering healthcare experience with SANCO.
- Patient Empowerment: Enables ALK+ NSCLC patients to actively participate in their care through self-monitoring.
- CANKADO PRO-React: A sophisticated tool for real-time symptom tracking and management.
- Quality of Life Enhancement: Focuses on improving patients’ daily living and well-being.
- Efficient Care Management: Streamlines the treatment process, reducing the burden on healthcare professionals.
Proactive Healthcare: Encourages early intervention for symptom management, promoting better health outcomes. To transform these insights into tailored treatments that address not just individual symptoms, but their interconnected impact on patient health.
Information
Get In Touch
Kyivstraße 9
81735 Munich
Germany
© 2024 CANKADO. All rights reserved.
Information
Contact
To contact call
Toll free number for Germany
You can also drop your message via contact page
Training
Check our Online Academy for further details
